Neurokinin-1 receptor antagonists

Preferred Label : Neurokinin-1 receptor antagonists;

MeSH definition : Compounds that inhibit or block the activity of NEUROKININ-1 RECEPTORS.;

MeSH synonym : antagonists, Neurokinin-1 receptor; neurokinin 1 receptor antagonists; receptor antagonists, Neurokinin-1; Neuroleukin-1 receptor blockers; blockers, Neuroleukin-1 receptor; neuroleukin 1 receptor blockers; receptor blockers, Neuroleukin-1; substance P receptor antagonists; tachykinin receptor 1 antagonists; tachykinin receptor 1 blockers; Neurokinin-1 receptor blockers; blockers, Neurokinin-1 receptor; neurokinin 1 receptor blockers; receptor blockers, Neurokinin-1; substance P receptor blockers; Tachykinin Receptor 1 Antagonist; Neurokinin 1 Receptor Antagonist; Neurokinin-1 Receptor Antagonist; Antagonist, Neurokinin-1 Receptor; Receptor Antagonist, Neurokinin-1; Neurokinin-1 Receptor Blocker; Blocker, Neurokinin-1 Receptor; Neurokinin 1 Receptor Blocker; Receptor Blocker, Neurokinin-1; Neuroleukin-1 Receptor Blocker; Blocker, Neuroleukin-1 Receptor; Neuroleukin 1 Receptor Blocker; Receptor Blocker, Neuroleukin-1; Tachykinin Receptor 1 Blocker; Substance P Receptor Blocker; Substance P Receptor Antagonist;

Wikipedia link : https://en.wikipedia.org/wiki/Neurokinin-1 receptor antagonists;

Is substance : O;

action pharmacologique : O;

Détails

Origin ID

D064729;

UMLS CUI

C3543440;

Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- analysis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Currated CISMeF NLP mapping
- NK 1 antagonists [CISMeF Querying Strategy]
- Substance with neurokinin 1 receptor antagonist mechanism of action (substance) [SNOMED CT concept]
MeSH Descriptor(s) used for indexing
- receptors, neurokinin-1 [MeSH Descriptor]
Record concept(s)
- Neurokinin-1 receptor antagonists [MeSH concept]
See also (suggested by CISMeF)
- NK 1 antagonists [CISMeF Querying Strategy]
See also inter- (CISMeF)
- Neurokinin 1 receptor antagonist (disposition) [SNOMED CT concept]
- Product containing neurokinin 1 receptor antagonist (product) [SNOMED CT concept]
Semantic type(s)
- Pharmacologic Substance [UMLS semantic type]
Substance(s)
- (2-fluoromethoxy-5-(5-trifluoromethyltetrazol-1-yl)benzyl)(2-phenylpiperidin-3-yl)amine [MeSH Supplementary Concept]
- (2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine [MeSH Supplementary Concept]
- 1-(4-(3,5-bis(trifluoromethyl)benzyloxymethyl)-4-phenylpiperidin-1-yl)-2-pyrrolidineacetamide [MeSH Supplementary Concept]
- 1-(N-(2-methoxybenzyl)acetylamino)-3-(1H-indol-3-yl)-2-(N-(2-(4-(piperidin-1-yl)piperidin-1-yl)acetyl)amino)propane [MeSH Supplementary Concept]
- 1-(amino(oxo)acetyl)-N-(1-(3,5-bis(trifluoromethyl)phenyl)ethyl)-3-(4-fluoro-2-methylphenyl)-N-methylpiperidine-4-carboxamide [MeSH Supplementary Concept]
- 1-oxo-7-azaspirodecane [MeSH Supplementary Concept]
- 2-(1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluoro)phenyl-4-(5-(2-phosphoryl-3-oxo-4H,-1,2,4-triazolo))methylmorpholine, bis(N-methylglucamine) salt [MeSH Supplementary Concept]
- 2-piperazin-1-ylindan-2-carboxylic acid (3-chloro-5-fluorobenzyl)methylamide [MeSH Supplementary Concept]
- 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine [MeSH Supplementary Concept]
- 3-(2-methoxy-5-trifluoromethoxybenzyl)amino-1-methyl-2-phenylpiperidine [MeSH Supplementary Concept]
- 3-(6-methoxy-1-methyl-1-trifluoromethylisochroman-7-yl)methylamino-2-phenylpiperidine [MeSH Supplementary Concept]
- 3-aryl-6-phenyl-1-oxa-7-azaspiro(4.5)decane [MeSH Supplementary Concept]
- 4-(3,5-bis(trifluoromethyl)benzyloxymethyl)-1-(2-methylthiazol-5-ylmethyl)-4-phenylpiperidine [MeSH Supplementary Concept]
- 6-diphenylmethyl-5-(5-isopropyl-2-methoxybenzylamino)-1-azabicyclo(2.2.2)octane-3-carboxylic acid [MeSH Supplementary Concept]
- 6-phenyl-1-oxa-7-azaspiro(4,5)decane [MeSH Supplementary Concept]
- 7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one [MeSH Supplementary Concept]
- ASN 1377642 [MeSH Supplementary Concept]
- AZD 2738 [MeSH Supplementary Concept]
- AZD 8081 [MeSH Supplementary Concept]
- Aprepitant [MeSH Descriptor]
- CAM 4515 [MeSH Supplementary Concept]
- CAM 4750 [MeSH Supplementary Concept]
- CI 1021 [MeSH Supplementary Concept]
- FK886 [MeSH Supplementary Concept]
- HSP 117 [MeSH Supplementary Concept]
- L 741671 [MeSH Supplementary Concept]
- L 743310 [MeSH Supplementary Concept]
- LY 306740 [MeSH Supplementary Concept]
- MDL 103392 [MeSH Supplementary Concept]
- MDL 105212A [MeSH Supplementary Concept]
- MDL 108,207DA [MeSH Supplementary Concept]
- MEN 10930 [MeSH Supplementary Concept]
- N-((2-cyclopropoxy-5-(5-trifluomethyl)tetrazol-1-yl)benzyl)-2-phenylpiperidin-3-amine [MeSH Supplementary Concept]
- N-((4-(2-cyanophenyl)piperazinyl)methyl)benzamide [MeSH Supplementary Concept]
- N-(1-(3,5-bis(trifluoromethyl)phenyl)ethyl)-7,8-dihydro-N,7-dimethyl-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide [MeSH Supplementary Concept]
- N-(3,5-bis(trifluoromethyl)benzyl)-7,8-dihydro-N,7-dimethyl-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide [MeSH Supplementary Concept]
- PD 174424 [MeSH Supplementary Concept]
- R116301 [MeSH Supplementary Concept]
- S 16474 [MeSH Supplementary Concept]
- S 18523 [MeSH Supplementary Concept]
- SDZ NKT 343 [MeSH Supplementary Concept]
- YM 35375 [MeSH Supplementary Concept]
- casopitant [MeSH Supplementary Concept]
- cyclo((2-naphthyl)alanyl-tryptophyl-(4-fluoro)phenylalanyl-threonyl-phenylalanyl-prolyl) [MeSH Supplementary Concept]
- fosaprepitant [MeSH Supplementary Concept]
- quinoline-4-carboxylic acid (1-(3,5-bis-trifluoromethylbenzoyl)-2-(4-chlorobenzyl)piperidin-4-yl)amide [MeSH Supplementary Concept]
- rolapitant [MeSH Supplementary Concept]
- sch 425078 [MeSH Supplementary Concept]
- serlopitant [MeSH Supplementary Concept]
- substance P, Arg(1)-Pro(2)-Phe(7)-His(9)- [MeSH Supplementary Concept]
- tyrosyl-alanyl-glycyl-phenylalanyl-methionyl-prolyl-leucyl-tryptophyl-O-3,5-benzyl(CF3)2 [MeSH Supplementary Concept]
- tyrosyl-alanyl-glycyl-phenylalanyl-norleucyl-prolyl-leucyl-tryptophyl-O-3,5-benzyl(CF3)2 [MeSH Supplementary Concept]
- tyrosyl-cyclo(penicillamine-glycyl-phenylalanyl-penicillamine)-prolyl-leucyl-tryptophyl-NH-(3',5'-(CF3)2-Bzl) [MeSH Supplementary Concept]
- vestipitant [MeSH Supplementary Concept]
- vofopitant [MeSH Supplementary Concept]
UMLS correspondences (same concept)
- Product containing neurokinin 1 receptor antagonist (product) [SNOMED CT concept]
- Substance with neurokinin 1 receptor antagonist mechanism of action (substance) [SNOMED CT concept]

Position du mot-clé dans l'(les) arborescence(s) :

Consulter ci-dessous une sélection des principales ressources :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients